Revisions to the proposed US-Mexico-Canada trade agreement have ‘fixed’ the replacement for the previous North American Free Trade Agreement, according to the US Association for Accessible Medicines. Along with the Canadian Generic Pharmaceutical Association, the AAM welcomed changes that included removing the requirement for a 10-year data exclusivity period for biologics and adding measures favorable to generics, including incentives for generic competition.
The changes followed recent rumors that US negotiators were preparing to scale back intellectual property provisions in the USMCA to...
